Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016

Elias J Dayoub; Ashwin S Nathan; Sameed Ahmed M Khatana; Matthew Seigerman; Sony Tuteja; Taisei Kobayashi; Daniel M Kolansky; Peter W Groeneveld; Jay Giri

doi:10.1161/CIRCINTERVENTIONS.118.007434

Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016

Circ Cardiovasc Interv. 2019 Jan;12(1):e007434. doi: 10.1161/CIRCINTERVENTIONS.118.007434.

Authors

Elias J Dayoub^{1

2

3}, Ashwin S Nathan^{2

3

4}, Sameed Ahmed M Khatana^{2

3

4}, Matthew Seigerman⁴, Sony Tuteja⁵, Taisei Kobayashi^{1

2

4}, Daniel M Kolansky⁴, Peter W Groeneveld^{1

2

3}, Jay Giri^{1

2

3

4}

Affiliations

¹ Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA (E.J.D., T.K., P.W.G., J.G.).
² Center for Cardiovascular Outcomes, Quality, and Evaluative Research, University of Pennsylvania (E.J.D., A.S.N., S.A.M.K., T.K., P.W.G., J.G.).
³ Leonard Davis Institute of Health Economics at the University of Pennsylvania (E.J.D., A.S.N., S.A.M.K., P.W.G., J.G.).
⁴ Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania (A.S.N., S.A.M.K., M.S., T.K., D.M.K., J.G.).
⁵ Department of Medicine, Hospital of the University of Pennsylvania (S.T.).

PMID: 30608869
PMCID: PMC6485954
DOI: 10.1161/CIRCINTERVENTIONS.118.007434

No abstract available

Keywords: acute coronary syndrome; clopidogrel; heart diseases; percutaneous coronary intervention; ticagrelor.

Publication types

Letter
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Clopidogrel / adverse effects
Clopidogrel / therapeutic use*
Cross-Sectional Studies
Databases, Factual
Drug Utilization / trends
Humans
Myocardial Ischemia / diagnostic imaging
Myocardial Ischemia / therapy*
Off-Label Use
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use*
Practice Patterns, Physicians' / trends*
Prasugrel Hydrochloride / adverse effects
Prasugrel Hydrochloride / therapeutic use*
Purinergic P2Y Receptor Antagonists / adverse effects
Purinergic P2Y Receptor Antagonists / therapeutic use*
Ticagrelor / adverse effects
Ticagrelor / therapeutic use*
Time Factors
Treatment Outcome
United States

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Clopidogrel
Prasugrel Hydrochloride
Ticagrelor

Grants and funding

T32 HL007843/HL/NHLBI NIH HHS/United States